

EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|-------|--------|----------------------------------|------------------------------|------------------|---------|------------------|
| L1 | 226807 | HIV fusion | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:44 |
| L2 | 940 | anti adj trypsin | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:45 |
| L3 | 7747 | antitrypsin | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:45 |
| L4 | 8326 | L2 or L3 | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:46 |
| L5 | 4639 | L4 and (alpha near3 antitrypsin) | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:46 |
| L6 | 915 | L4 and (alpha near4 trypsin) | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:48 |
| L7 | 65 | L4 and (AAT near3 sequence) | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:48 |

EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|-------|--------|----------------------------------|------------------------------|------------------|---------|------------------|
| L1 | 226807 | HIV fusion | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:44 |
| L2 | 940 | anti adj trypsin | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:45 |
| L3 | 7747 | antitrypsin | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:45 |
| L4 | 8326 | L2 or L3 | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:46 |
| L5 | 4639 | L4 and (alpha near3 antitrypsin) | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:46 |
| L6 | 915 | L4 and (alpha near4 trypsin) | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:48 |
| L7 | 65 | L4 and (AAT near3 sequence) | US-PGPUB; USPAT; USOCR | OR | ON | 2007/02/23 11:48 |

| | | | | | | | |
|----|-------------|----|----------|-------|---------|---|-------|
| US | 20070003943 | A1 | US-PGPUB | US | 5714345 | A | USPAT |
| US | 20060269536 | A1 | US-PGPUB | US | 5668107 | A | USPAT |
| US | 20060246074 | A1 | US-PGPUB | US | 5650503 | A | USPAT |
| US | 20060057117 | A1 | US-PGPUB | US | 5648254 | A | USPAT |
| US | 20060040867 | A1 | US-PGPUB | US | 5622930 | A | USPAT |
| US | 20050277106 | A1 | US-PGPUB | US | 5525494 | A | USPAT |
| US | 20050232921 | A1 | US-PGPUB | US | 5439824 | A | USPAT |
| US | 20050201951 | A1 | US-PGPUB | US | 5420110 | A | USPAT |
| US | 20050192429 | A1 | US-PGPUB | US | 5412073 | A | USPAT |
| US | 20050181979 | A1 | US-PGPUB | US | 4937324 | A | USPAT |
| US | 20050137156 | A1 | US-PGPUB | | | | |
| US | 20050137153 | A1 | US-PGPUB | | | | |
| US | 20050124010 | A1 | US-PGPUB | | | | |
| US | 20050084972 | A1 | US-PGPUB | | | | |
| US | 20050059117 | A1 | US-PGPUB | | | | |
| US | 20050026838 | A1 | US-PGPUB | | | | |
| US | 20040175383 | A1 | US-PGPUB | | | | |
| US | 20040143103 | A1 | US-PGPUB | | | | |
| US | 20040142416 | A1 | US-PGPUB | | | | |
| US | 20040077090 | A1 | US-PGPUB | | | | |
| US | 20030215921 | A1 | US-PGPUB | | | | |
| US | 20030176674 | A1 | US-PGPUB | | | | |
| US | 20030175274 | A1 | US-PGPUB | | | | |
| US | 20030170786 | A1 | US-PGPUB | | | | |
| US | 20030138784 | A1 | US-PGPUB | | | | |
| US | 20030113388 | A1 | US-PGPUB | | | | |
| US | 20030073217 | A1 | US-PGPUB | | | | |
| US | 20030053998 | A1 | US-PGPUB | | | | |
| US | 20030033634 | A1 | US-PGPUB | | | | |
| US | 20030028007 | A1 | US-PGPUB | | | | |
| US | 20020164695 | A1 | US-PGPUB | | | | |
| US | 20020160402 | A1 | US-PGPUB | | | | |
| US | 20020155508 | A1 | US-PGPUB | | | | |
| US | 20020150940 | A1 | US-PGPUB | | | | |
| US | 20020146733 | A1 | US-PGPUB | | | | |
| US | 20020131961 | A1 | US-PGPUB | | | | |
| US | 20020120953 | A1 | US-PGPUB | | | | |
| US | 20020082224 | A1 | US-PGPUB | | | | |
| US | 7049098 | B2 | | USPAT | | | |
| US | 7045354 | B2 | | USPAT | | | |
| US | 7033781 | B1 | | USPAT | | | |
| US | 7018833 | B2 | | USPAT | | | |
| US | 6924267 | B2 | | USPAT | | | |
| US | 6919493 | B2 | | USPAT | | | |
| US | 6900018 | B2 | | USPAT | | | |
| US | 6734285 | B2 | | USPAT | | | |
| US | 6680425 | B1 | | USPAT | | | |
| US | 6548735 | B1 | | USPAT | | | |
| US | 6410241 | B1 | | USPAT | | | |
| US | 6127145 | A | | USPAT | | | |
| US | 6083902 | A | | USPAT | | | |
| US | 6066781 | A | | USPAT | | | |
| US | 6048973 | A | | USPAT | | | |
| US | 5861299 | A | | USPAT | | | |
| US | 5736379 | A | | USPAT | | | |

ANDERMANN 10 / 539 627 = anti-HIV peptides approx. 20-mers

LOGINID: SSPTAHPY1654

FILE 'HOME' ENTERED AT 12:21:54 ON 23 FEB 2007

=> s LEAIPM/sqsp
L1 291 LEAIPM/SOSP

FILE 'CAPLUS' ENTERED AT 12:23:47 ON 23 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Feb 2007 VOL 146 ISS 10
FILE LAST UPDATED: 22 Feb 2007 (20070222/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s L1 and PATENT/dt  
          143 L1  
      5614010 PATENT/DT  
L2          114 L1 AND PATENT/DT
```

=> dup rem L2
PROCESSING COMPLETED FOR L2
L3 112 DUP REM L2 (2 DUPLICATES REMOVED)

=> d L3 1-12 bib abs

L3 ANSWER 1 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:53944 CAPLUS

DN 146:178407
TI Predicting sites for hydroxyproline glycosylation in secreted plant
proteins and their use in developing secretory expression systems
IN Kieliszewski, Marcia J.; Xu, Jianfeng

PA Ohio University, USA
SO PCT Int. Appl., 112pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2007008708 | A2 | 20070118 | WO 2006-US26594 | 20060710 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, -FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRAI US 2005-697337P P 20050708

AB Proteins glycosylated at hydroxyproline residues are more likely to be efficiently secreted from plant cells than are protein without these modifications. Methods for the prediction of sites for proline hydroxylation and hydroxyproline glycosylation in proteins are described. These methods include a series of tests in which the protein sequence is checked by sets of rules with the passing or failing of the test sending it to new tests. Such methods can be used to identify non-plant proteins that have the motifs assocd. with these processes and so likely to become glycosylated in plant cells, and to identify sites in non-plant proteins that can be converted into hydroxyproline glycosylation sites to increase the efficiency of secretion. It is also possible to det. empirically whether a particular protein will undergo hydroxyproline glycosylation suitable for the desired level of secretion in plant cells.

L3 ANSWER 2 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:38162 CAPLUS

DN 146:135565

TI Compositions containing neutral lipids and lung surfactant proteins for treatment of respiratory diseases

IN Chochrane, Charles G.

PA The Scripps Research Institute, USA

SO PCT Int. Appl., 94pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2007005672 | A2 | 20070111 | WO 2006-US25705 | 20060630 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, -FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRAI US 2005-695830P P 20050630
AB The invention provides compns. and methods for treating respiratory diseases and conditions. Such compns. and methods utilize a neutral lipid combined with a lung surfactant polypeptide. Thus, a model compn. contains (KLLLL)4K, 1,2-dipalmitoylphosphatidylcholine, 1-palmitoyl-2-oleoyl phosphatidylglycerol, cholesterol, and palmitic acid in an aq. buffer.

L3 ANSWER 3 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1312194 CAPLUS
DN 146:55493
TI Methods for reducing graft rejection and promotion of graft survival using compositions comprising serine protease inhibitors, such as .alpha.1-anti-trypsin
IN Shapiro, Leland; Lewis, Eli C.; Dinarello, Charles A.
PA The Regents of the University of Colorado, USA
SO PCT Int. Appl., 81pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----|--|------|----------|-----------------|----------|
| PI | WO 2006133403 | A2 | 20061214 | WO 2006-US22436 | 20060607 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRAI US 2005-687850P P 20050607
AB The invention provides methods for reducing the risk of a transplant rejection, such as graft rejection, or side-effects thereof, which involve administration of serine protease inhibitor, such as .alpha.1-anti-trypsin, in combination with anti-transplant agents. The invention also provides methods for treating a subject in need of immunotolerance therapy and/or for preserving an explanted organ or non-organ, which involve administration of a compd. with .alpha.1-anti-trypsin-like activity or a compd. with serine protease inhibiting activity. The invention relates that immunotolerance therapy is selected from group consisting of reducers of apoptosis prodn., reducers of cytokine prodn., reducers of nitric oxide prodn. and a combination thereof.

L3 ANSWER 4 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1252610 CAPLUS
DN 146:23034
TI Biomarkers for breast cancer
IN Li, Jinong; Sukumar, Saraswati; Chan, Daniel W.
PA The Johns Hopkins University, USA
SO PCT Int. Appl., 63pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2006128082 | A2 | 20061130 | WO 2006-US20643 | 20060525 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRAI US 2005-685459P P 20050526

AB The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.

L3 ANSWER 5 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:888486 CAPLUS
 DN 145:299200
 TI Cloning and application of proteinase inhibitor genes in transgenic mouse for serpin-related antiinflammation study
 IN Ashton-Rickardt, Philip G.; Zhang, Manling
 PA University of Chicago, USA
 SO PCT Int. Appl., 243pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2006091773 | A2 | 20060831 | WO 2006-US6524 | 20060224 |
| | WO 2006091773 | A3 | 20061221 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRAI US 2005-656492P P 20050225

AB Disclosed are compns. and methods related to serpins and their function as well as methods related to mechanisms dependent on the serpins. Proteinase inhibitor genes Spi6 and PI9 were cloned and transgenic mice were prep'd. for serpin-related antiinflammation study.

L3 ANSWER 6 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:888497 CAPLUS
 DN 145:287515
 TI Design of recombinant protein inhibitors of human kallikrein 14 containing reactive serpin loop, and use for treatment of proteolysis-related disorders.
 IN Deperthes, David; Kuendig, Christoph; Cloutier, Sylvain; Felber, Loyse
 PA Universite De Lausanne, Switz.
 SO PCT Int. Appl., 101pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2006090282 | A2 | 20060831 | WO 2006-IB574 | 20060228 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRAI WO 2005-IB504 A 20050228

AB The present invention relates to a recombinant inhibitor protein of an hK14 protease (human kallikrein 14) comprising a Reactive Serpin Loop of a serpin sequence which is modified by at least one substrate active site sequence specific for said hK14 protease. Other objects of the invention are to provide a purified and isolated nucleic acid sequence encoding the recombinant inhibitor protein of said hK14 protease, an expression vector comprising said purified and isolated nucleic acid sequence, a eukaryotic or prokaryotic host cell transformed with this expression vector and a method of producing a recombinant inhibitor protein of an hK14 protease. The hK14 inhibitor of the invention can be used for treatment of a proteolysis-related disorder, such as: cancer, inflammation, infection or autoimmune disorder. The nucleotide sequences and the encoded amino acid sequences of hK14 inhibitor proteins based on .alpha.1-antichymotrypsin and .alpha.1-antitrypsin are provided.

I3 ANSWER 7 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:771285 CAPLUS

DN 145:204044

TI Leader sequences for directing secretion and production of polypeptides

IN Halenbeck, Robert Forgan; Bosch, Elizabeth; Linnemann, Thomas; Lee, Ernestine

PA Five Prime Therapeutics, Inc., USA

SO PCT Int. Appl., 86pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 19

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2006081430 | A2 | 20060803 | WO 2006-US2951 | 20060127 |
| | WO 2006081430 | A9 | 20061130 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRAI US 2005-647013P P 20050127

AB The present invention provides nucleic acid and polypeptide constructs for producing proteins in higher yields than when such proteins are produced from sequences that comprise their endogenous signal peptide. Higher yields are achieved either by replacing the endogenous secretory leader sequence with an heterologous secretory sequence, or by adding a heterologous secretory leader sequence to a protein that would otherwise not contain a leader sequence. Accordingly, polypeptide and polynucleotide constructs are provided where the polypeptides and polynucleotides are modified so as to form a fusion mol. with a fusion partner. Leader sequences that are useful for the prodn. of heterologous secretable polypeptides, heterologous secreted polypeptides, nucleic acid constructs that encode such leader sequences and heterologous secreted polynucleotides, vectors and recombinant host cells that contain such nucleic acid constructs, and methods of making and using such secreted polypeptides with such heterologous leader sequences are provided.

L3 ANSWER 8 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:735861 CAPLUS

DN 145:195556

TI Use of tubercidin or SSM/SSMA for treatment of viral infections

IN Katz, Harvey; King, Colm J.; Shapiro, Leland

PA Hard To Treat Diseases, Inc., USA; The Regents of the University of Colorado

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2006078369 | A2 | 20060727 | WO 2005-US44834 | 20051212 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2004-636091P | P | 20041216 | | |

AB A novel method of treating and preventing viral diseases is provided. In particular, the present invention relates to compns. and methods for inhibition of viral infections and the diseases assocd. with such viral infections. More particularly, the present invention relates to the inhibitory compds. comprising naturally occurring and man-made compns. comprising a substance exhibiting Tubercin and/or SSM activity or a functional deriv. thereof. Thus, tubercidin and SSMA inhibited IL-18-induced HIV-1 prodn. by U1 cells in a dose-dependent manner. Neither tubercidin nor SSMA were toxic to the U1 cells. Tubercidin also inhibited HIV-1 prodn. in infected PBMC. The earliest stages of HIV-1 infection was inhibited by tubercidin in an in vitro model of HIV-1 infection.

L3 ANSWER 9 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:236707 CAPLUS

DN 144:267306

TI Using .alpha.1-antitrypsin as biomarkers and therapeutic targets for cognitive decline

IN Schmechel, Donald E.; Browndyke, Jeffery N.; Welsh-Bohmer, Kathleen A.;

Sansing-Edwards, Kathy L.

PA Duke University, USA

SO PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2006028586 | A2 | 20060316 | WO 2005-US26180 | 20050722 |
| | WO 2006028586 | A3 | 20060713 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRAI US 2004-589795P P 20040722

AB The present invention relates to a method for predicting rate of progression of central nervous system diseases by detg. types of alleles of .alpha.1-antitrypsin (AAT) or AAT level in the subject, using the detd. types of alleles or AAT level as a factor to predict rate of progression of cognitive and/or behavioral decline in the subject. Enrichment of S and Z polymorphisms of AAT in distinct subsets of patients with cognitive disorder (pre-existing affective disorders and APOE2 allele carriers) suggests that AAT variants are potential endophenotypes for Alzheimer Disease and related disorders of cognition, behavior and affect. Such disorders include ADD/ADHD, learning disabilities, ADEM, and susceptibility to brain injury in toxic/chem./biol./immunol. events. In Alzheimer Disease, S and Z alleles affect age of onset and low AAT levels define faster progression rate. Twenty to thirty percent of all dementia patients display AAT and/or We polymorphisms. Effects of AAT may involve inflammation of liver/lung, macrophage activation and iron and lipid metab. AAT, its regulation, and iron metab. represent therapeutic targets and AAT can serve as a biomarker for vulnerability and disease progression.

L3 ANSWER 10 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:75151 CAPLUS

DN 144:169110

TI Biomarkers and methods for diagnosis of ovarian cancer

IN Beyer, Wayne F., Jr.; Venetta, Thomas Michael; Groelke, John W.; Blaesius, Rainer H.

PA Tripath Imaging, Inc., USA

SO PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|------|----------|-----------------|----------|
| PI | WO 2006010047 | A2 | 20060126 | WO 2005-US24359 | 20050708 |
| | WO 2006010047 | A3 | 20061221 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

US 2006029956 A1 20060209 US 2005-177506 20050708

PRAI US 2004-586856P P 20040709

AB Methods and compns. for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in ovarian cancer. In preferred embodiments, the body sample is a serum sample. The biomarkers of the invention include any genes or proteins that are selectively overexpressed in ovarian cancer, including, for example, acute phase reactants, lipoproteins, proteins involved in the regulation of the complement system, regulators of apoptosis, proteins that bind Hb, heme, or iron, cytostructural proteins, enzymes that detoxify metabolic byproducts, growth factors, and hormone transporters. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.

L3 ANSWER 11 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1178630 CAPLUS

DN 145:485561

TI Novel liver cancer biomarkers, and liver cancer detection method using these biomarkers

IN Uchida, Kazuhiko; Katagiri, Takuya; Sato, Yumi; Fujimoto, Hirotaka

PA MCBI, Inc., Japan; Shimazu Corporation

SO Jpn. Kokai Tokkyo Koho, 24pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | JP 2006308533 | A | 20061109 | JP 2005-134627 | 20050502 |
| PRAI | JP 2005-134627 | | 20050502 | | |

AB A liver cancer detection method is provided, which uses as a biomarker a protein(s) or its partial peptide(s) whose presence/absence or abundance is different between normal persons and liver cancer patients. The detection is carried out by an immunoassay using an enzyme- or fluorescent-labeled antibody or a mass spectrometry. Also provided is a liver cancer detection biomarker(s) comprising this protein(s) or its peptide(s) which is at least one protein or peptide selected from a group of fibrinogen .alpha. chain consisting of the amino acid sequence expressed with SEQ ID NO 1, fibrinopeptide A like consisting of the amino acid sequence expressed with SEQ ID NO 3, complement C4A consisting of the amino acid sequence expressed with SEQ ID NO 5, inter-.alpha. trypsin inhibitor consisting of the amino acid sequence expressed with SEQ ID NO 7, gelsolin consisting of the amino acid sequence expressed with SEQ ID NO 9, apolipoprotein A1 consisting of the amino acid sequence expressed with SEQ ID NO 11., .alpha.2 macroglobulin consisting of the amino acid sequence expressed with SEQ ID NO 13, and .alpha.1-antitrypsin consisting of the amino acid sequence expressed with SEQ ID NO 15. This group of proteins and peptides further include the fibrinogen .alpha. chain partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 2, the fibrinopeptide A like partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 4, the complement C4A partial peptide

consisting of the amino acid sequence expressed with SEQ ID NO 6, the inter-.alpha. trypsin inhibitor partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 8, the gelsolin partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 10, the apolipoprotein A1 partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 12, the .alpha.2 macroglobulin partial peptide consisting of the amino acid sequence expressed with SEQ ID 14, the .alpha.1-antitrypsin partial peptide consisting of the amino acid sequence expressed with SEQ ID 16, and the inter-.alpha. trypsin inhibitor heavy chain H4 precursor partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 17.

L3 ANSWER 12 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1091555 CAPLUS
DN 145:434454
TI External diagnostic system based on protein, part protein/part peptide, or its profile
IN Uchida, Kazuhiko; Katagiri, Takuya; Fujimoto, Hirotaka
PA Mcbi, Inc., Japan; Shimazu Corporation
SO Jpn. Kokai Tokkyo Koho, 33pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------|------|----------|-----------------|----------|
| PI JP 2006284389 | A | 20061019 | JP 2005-105309 | 20050331 |
| PRAI JP 2005-105309 | | 20050331 | | |

AB A method is provided for externally evaluating/identifying with a living body the normal state, the state other than the normal state including disease state (e.g., inflammation, precancerous lesion, cancer, advanced cancer), or the progress degree of disease state. In this method, used as a marker is at least one of an intact particular protein or its part protein/peptide (e.g., proteinase digestion product) in the case where the protein exists as an intact protein with the living body in the normal state while the protein exists as at least one part protein/peptide. The method comprises measuring the kind, abundance and/or abundance ratio of the intact protein, its part protein and/or its part peptide in a biol. sample (e.g., blood) by an immunoassay, a mass spectrometry or else, and thereby, obtaining a protein/part peptide profile.

=> d L3 100-112 bib abs

L3 ANSWER 100 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:603982 CAPLUS
DN 123:190539
TI cDNA sequences for human .alpha.1-antitrypsin
IN Davie, Earl W.; Kurachi, Kotoku; Woo, Savio L. C.; Thirumalachary, Chandra
PA Washington Research Foundation, USA
SO U.S., 15 pp. Cont. of U.S. Ser. No. 979,556, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------|------|----------|-----------------|----------|
| PI US 5399684 | A | 19950321 | US 1993-86442 | 19930702 |
| US 5736379 | A | 19980407 | US 1995-479545 | 19950607 |
| US 6025161 | A | 20000215 | US 1998-9581 | 19980120 |
| PRAI US 1982-380310 | B1 | 19820520 | | |
| US 1984-638980 | B1 | 19840207 | | |
| US 1987-22543 | B1 | 19870303 | | |

| | | |
|----------------|----|----------|
| US 1987-133190 | B1 | 19871215 |
| US 1988-246912 | B1 | 19880916 |
| US 1989-398288 | B1 | 19890822 |
| US 1991-666450 | B1 | 19910311 |
| US 1992-979556 | B1 | 19921118 |
| US 1993-86442 | A1 | 19930702 |
| US 1994-361689 | B1 | 19941212 |
| US 1995-479545 | A3 | 19950607 |

AB A cDNA encoding human .alpha.1-antitrypsin is cloned and characterized for use in the study of .alpha.1-antitrypsin in disease. .alpha.1-Antitrypsin is an important protease inhibitor present in mammalian blood. Its major physiol. function appears to be the inhibition of neutrophil elastase, a potent protease that hydrolyzes structural proteins. In order to study .alpha.1-antitrypsin deficiency at the mol. level, it is desirable to obtain pure polypeptide. This .alpha.1-antitrypsin polypeptide may be used for the formation of antibodies to numerous determinant sites for detection of variants in the blood. Also, this may be used for introduction into a host having .alpha.1-antitrypsin deficiency. Therefore, cDNA sequences for human .alpha.1-antitrypsin were cloned and may be used for expression of mammalian .alpha.1 -antitrypsin.

L3 ANSWER 101 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:446653 CAPLUS

DN 122:259856

TI Thermoresistant amino acid-substituted analogs of .alpha.1-antitrypsin

IN Yu, Myeong-Hee; Kwon, Ki-Sun; Lee, Kee Nyung; Shin, Hwa Soo

PA Korea Institute of Science and Technology, S. Korea; Korea Green Cross Corp

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|-----------|-----------------|----------|
| PI | WO 9426781 | A1 | 19941124 | WO 1994-KR48 | 19940517 |
| | W: CA, JP, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2163081 | A1 | 19941124 | CA 1994-2163081 | 19940517 |
| | CA 2163081 | C | 200000314 | | |
| | EP 701570 | A1 | 19960320 | EP 1994-915692 | 19940517 |
| | EP 701570 | B1 | 20011219 | | |
| | R: BE, CH, DE, DK, FR, GB, IT, LI, NL, SE | | | | |
| | JP 08509865 | T | 19961022 | JP 1994-525260 | 19940517 |
| | KR 133252 | B1 | 19980414 | KR 1994-10902 | 19940519 |
| | US 5817484 | A | 19981006 | US 1995-553488 | 19951121 |
| PRAI | KR 1993-8510 | A | 19930518 | | |
| | WO 1994-KR48 | W | 19940517 | | |

AB Analogs of .alpha.1-antitrypsin (AT) that have amino acid substitutions that improve the resistance of the protein to heat are manufd. by expression of the cloned gene. Increased thermostability indicates an overall resistance to denaturation and may indicate a greater utility of these analogs as therapeutics. A no. of analogs with near normal activity and greater thermostability are prep'd. by random or site-directed mutagenesis of a cloned gene and manuf. of the protein in Escherichia coli. Analogs with Phe-51 replaced by Cys showed normal activity and less extensive aggregation at 55.degree. than the wild-type inhibitor.

L3 ANSWER 102 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1993:109675 CAPLUS

DN 118:109675

TI Compositions and methods for inhibiting elastase

IN Miller, Edward J.

PA Uab Research Foundation, USA
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------|--|------|----------|-----------------|----------|
| PI | WO 9218141 | A1 | 19921029 | WO 1992-US3207 | 19920417 |
| | W: CA, JP | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE | | | | |
| | CA 2108689 | A1 | 19921019 | CA 1992-2108689 | 19920417 |
| | EP 616614 | A1 | 19940928 | EP 1992-911506 | 19920417 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE | | | | |
| | JP 06509327 | T | 19941020 | JP 1992-511411 | 19920417 |
| | US 5668107 | A | 19970916 | US 1995-437029 | 19950508 |
| PRAI | US 1991-687372 | A | 19910418 | | |
| | WO 1992-US3207 | W | 19920417 | | |
| | US 1992-919992 | A3 | 19920727 | | |
| AB | A polypeptide moiety, in a suitable carrier, having an identifying no. of amino acids for C-terminal fragment of .alpha.1-antitrypsin (SPAAT), with collagen-, elastin-, and neutrophil elastase-binding activities is developed. The polypeptide can be used for the treatment of pulmonary emphysema and adult respiratory distress syndrome (no data). Isolation, biochem. characterization, protein sequencing, inhibition of enzyme activity, and binding to proteins of SPAAT were given. | | | | |
| L3 | ANSWER 103 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN | | | | |
| AN | 1992:537663 CAPLUS | | | | |
| DN | 117:137663 | | | | |
| TI | Antitumor molecules which bind to a tumor cell and inhibit a tumor-associated protease | | | | |
| IN | Ballance, David James; Courtney, Michael George | | | | |
| PA | Delta Biotechnology Ltd., UK | | | | |
| SO | Brit. UK Pat. Appl., 57 pp. | | | | |
| | CODEN: BAXXDU | | | | |
| DT | Patent | | | | |
| LA | English | | | | |
| FAN.CNT 1 | | | | | |
| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
| PI | GB 2246779 | A | 19920212 | GB 1990-17083 | 19900803 |
| | GB 2246779 | B | 19940817 | | |
| | WO 9202553 | A1 | 19920220 | WO 1991-GB1322 | 19910802 |
| | W: AU, CA, JP, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE | | | | |
| | AU 9183185 | A | 19920302 | AU 1991-83185 | 19910802 |
| PRAI | GB 1990-17083 | A | 19900803 | | |
| | WO 1991-GB1322 | A | 19910802 | | |
| AB | Mols. comprising a 1st region which binds to a tumor cell and a 2nd region which inhibits a tumor-assocd. protease are prep'd. for treating tumors. The 2 regions may be combined by chem. linking them or by expressing a nucleotide sequence encoding the 2 regions as a single polypeptide in a host transformed with the nucleotide sequence. Recombinant prepn. of fusion proteins contg. a methionine residue followed by amino acid residues 1-47 of urokinase-type plasminogen activator (uPA) and then plasminogen activator inhibitor 2 (PAI-2) or .alpha.1-antitrypsin Pittsburgh is described. | | | | |

L3 ANSWER 104 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1991:672672 CAPLUS
 DN 115:272672
 TI Cloning and expression of human serine proteinase inhibitor cDNA

IN Kalsheker, Noor Ahmed
 PA 3i Research Exploitation Ltd., UK
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------|--|------|----------|-----------------|----------|
| PI | WO 9109947 | A1 | 19910711 | WO 1990-GB2003 | 19901221 |
| | W: CA, JP, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE | | | | |
| | CA 2070399 | A1 | 19910623 | CA 1990-2070399 | 19901221 |
| | EP 506755 | A1 | 19921007 | EP 1991-901314 | 19901221 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | JP 05502376 | T | 19930428 | JP 1991-501703 | 19901221 |
| | US 5412073 | A | 19950502 | US 1992-859480 | 19920616 |
| PRAI | GB 1989-29110 | A | 19891222 | | |
| | WO 1990-GB2003 | W | 19901221 | | |
| AB | The cDNA for a human serine proteinase inhibitor of mol. wt. 32 .+- . 1 kilodaltons (unglycosylated) is cloned and expressed in Escherichia coli. The inhibitor may be useful in treatment of emphysema, arthritis, or septic shock. Human liver cDNA was screened with a DNA probe corresponding to the .alpha.1-antitrypsin gene to identify clone pAT153 contg. the proteinase inhibitor cDNA of the invention. | | | | |
| L3 | ANSWER 105 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN | | | | |
| AN | 1992:102250 CAPLUS | | | | |
| DN | 116:102250 | | | | |
| TI | .alpha.-1-Antitrypsin peptide and monoclonal antibodies and kit for diagnosis of .alpha.-1-antitrypsin deficiency | | | | |
| IN | Jeppsson, Jan Olof | | | | |
| PA | Ferring AB, Swed. | | | | |
| SO | PCT Int. Appl., 18 pp. | | | | |
| | CODEN: PIXXD2 | | | | |
| DT | Patent | | | | |
| LA | English | | | | |
| FAN.CNT 1 | | | | | |
| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
| PI | WO 9108488 | A1 | 19910613 | WO 1990-SE768 | 19901123 |
| | W: AU, CA, FI, NO, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE | | | | |
| | AU 9178968 | A | 19910626 | AU 1991-78968 | 19901123 |
| PRAI | SE 1989-4007 | A | 19891128 | | |
| | WO 1990-SE768 | A | 19901123 | | |
| OS | MARPAT 116:102250 | | | | |
| AB | The decapeptide HX1-Leu-Thr-Ile-Asp-Lys-Lys-Gly-Thr-Gly-Ala-X2Y (X1,X2 = optional coupling-facilitating amino acid; Y = NH2, OH) is used to produce monoclonal antibodies that bind to a single epitope on [Lys342].alpha.1-antitrypsin for in vitro diagnosis of .alpha.1-antitrypsin deficiency. Thus, H-Leu-Thr-Ile-Asp-Lys-Lys-Gly-Thr-Gly-Ala-Cys-OH was conjugated to hemocyanin to produce the above antibodies. Anal. of blood serum by time-resolved fluorescence using the monoclonal antibodies was able to distinguish homozygous PiZ (deficient, ZZ) individuals from heterozygous PiZ (predisposed, MZ) and normal (MM) individuals. | | | | |

L3 ANSWER 106 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1991:466184 CAPLUS
 DN 115:66184
 TI Fusion proteins containing N-terminal fragments of human serum albumin
 IN Ballance, David James

PA Delta Biotechnology Ltd., UK
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9013653 | A1 | 19901115 | WO 1990-GB650 | 19900426 |
| | W: AU, FI, GB, HU, JP, KR, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE | | | | |
| | AU 9055646 | A | 19901129 | AU 1990-55646 | 19900426 |
| | AU 630450 | B2 | 19921029 | | |
| | EP 470165 | A1 | 19920212 | EP 1990-907285 | 19900426 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE | | | | |
| | JP 04506598 | T | 19921119 | JP 1990-506978 | 19900426 |
| | HU 61049 | A2 | 19921130 | HU 1990-4413 | 19900426 |
| | CA 2015687 | A1 | 19901029 | CA 1990-2015687 | 19900427 |
| | CA 2015687 | C | 20000829 | | |
| | ZA 9003237 | A | 19910327 | ZA 1990-3237 | 19900427 |
| | IL 94243 | A | 19951031 | IL 1990-94243 | 19900429 |
| | GB 2246783 | A | 19920212 | GB 1991-19043 | 19910906 |
| | GB 2246783 | B | 19921014 | | |
| | FI 104255 | B | 19991215 | FI 1991-5073 | 19911028 |
| | FI 104255 | B1 | 19991215 | | |
| | US 5766883 | A | 19980616 | US 1993-153799 | 19931117 |
| PRAI | GB 1989-9916 | A | 19890429 | | |
| | WO 1990-GB650 | A | 19900426 | | |
| | US 1991-775952 | B2 | 19911029 | | |
| | US 1992-847975 | B1 | 19920306 | | |

AB Recombinant fusion proteins comprising an N-terminus derived from human serum albumin (HSA) or an HSA variant fused to a C-terminus which is not HSA, e.g. a human fibronectin fragment, a CD4 fragment, platelet-derived growth factor, transforming growth factor .beta., a von Willebrand's factor fragment, or .alpha.-1-antitrypsin. The HSA N-terminus favors secretion of the fusion proteins from eukaryotic cells. Plasmids encoding HSA 1-387 or HSA 1-195 fused to human fibronectin 585-1578 were prep'd. *Saccharomyces cerevisiae* transformed with these plasmids produced and secreted the fusion proteins.

L3 ANSWER 107 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:527705 CAPLUS
DN 113:127705

TI Regulated expression vectors for yeast
IN Burke, Rae L.; Rosenberg, Steven; Shuster, Jeffrey R.; Tekamp-Olson, Patricia; Valenzuela, Pablo D. T.; Barr, Philip J.
PA Chiron Corp., USA
SO U.S., 32 pp. Cont. of U.S. Ser. No. 760,197.

CODEN: USXXAM

DT Patent
LA English

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 4880734 | A | 19891114 | US 1986-868639 | 19860529 |
| | AT 93894 | T | 19930915 | AT 1989-106868 | 19840106 |
| | EP 732403 | A1 | 19960918 | EP 1996-200286 | 19840106 |
| | R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| | US 4876197 | A | 19891024 | US 1985-760197 | 19850729 |
| | US 5089398 | A | 19920218 | US 1989-380783 | 19890718 |
| | US 5349059 | A | 19940920 | US 1993-42134 | 19930402 |
| | US 35749 | E | 19980317 | US 1996-710744 | 19960920 |
| PRAI | US 1983-468589 | A2 | 19830222 | | |

| | | |
|----------------|----|----------|
| US 1984-609540 | A2 | 19840511 |
| US 1985-760197 | A2 | 19850729 |
| EP 1989-106868 | A | 19840106 |
| EP 1991-114001 | A3 | 19840106 |
| US 1987-73381 | B1 | 19870713 |
| US 1989-380783 | A1 | 19890718 |
| US 1990-635048 | B1 | 19901228 |
| US 1993-42134 | A5 | 19930402 |

AB Expression cassettes for use in yeast use regulated or constitutive promoters from yeast genes coupled to the transcription initiation and termination sequences of the yeast glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene are used to attain high levels of expression of heterologous genes. A human superoxide dismutase (SOD) was cloned and expressed in yeast from the GAPDH transcription start site alone or with the GAL4 promoter as regulatable promoter. Expression of the gene in yeast without the GAL promoter resulted in SOD levels of 148 .mu.g SOD/mg (in a medium contg. lactate and glycerol as C sources). Under control of the GAL promoter levels of prodn. in this medium were 0.4 .mu.g SOD/mg protein, if the C source was galactose the yield reached 68 .mu.g SOD/mg protein.

L3 ANSWER 108 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1990:453717 CAPLUS

DN 113:53717

TI Expression of foreign genes in yeast from strongly regulated yeast promoters

IN Burke, Rae Lyn; Rosenberg, Steven; Shuster, Jeffrey R.; Tekamp-Olson, Patricia A.; Valenzuela, Pablo D. T.

PA Chiron Corp., USA

SO U.S., 28 pp. Cont.-in-part of U.S. Ser. No. 468,589, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 4876197 | A | 19891024 | US 1985-760197 | 19850729 |
| | AT 93894 | T | 19930915 | AT 1989-106868 | 19840106 |
| | EP 732403 | A1 | 19960918 | EP 1996-200286 | 19840106 |
| | R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| | US 4880734 | A | 19891114 | US 1986-868639 | 19860529 |
| | US 5089398 | A | 19920218 | US 1989-380783 | 19890718 |
| | US 5349059 | A | 19940920 | US 1993-42134 | 19930402 |
| | US 35749 | E | 19980317 | US 1996-710744 | 19960920 |
| PRAI | US 1983-468589 | A2 | 19830222 | | |
| | US 1984-609540 | A2 | 19840511 | | |
| | EP 1989-106868 | A | 19840106 | | |
| | EP 1991-114001 | A3 | 19840106 | | |
| | US 1985-760197 | A2 | 19850729 | | |
| | US 1987-73381 | B1 | 19870713 | | |
| | US 1989-380783 | A1 | 19890718 | | |
| | US 1990-635048 | B1 | 19901228 | | |
| | US 1993-42134 | A5 | 19930402 | | |

AB Plasmid constructs contg. regulatory sequences that allow strong, regulated expression of heterologous genes in yeast are described. The transcription initiation region of the glyceraldehyde-3-phosphate dehydrogenase gene and promoters from ADR3, PHO5, or the GAL1-GAL10 intergenic region are used. A chimeric gene encoding a human proinsulin-superoxide dismutase fusion gene was constructed and expressed from a yeast glyceraldehyde-3-phosphate dehydrogenase promoter (GAP) or a chimeric alc. dehydrogenase-GAP promoter. Depending on the promoter used, and the linker between the two domains of the fusion protein, the gene product was up to 10% of total cell protein. The expression of the

proinsulin gene alone from the GAP promoter or as a fusion protein with yeast pyruvate kinase expressed from the pyruvate kinase promoter resulted in proinsulin constituting <0.1% of total protein.

L3 ANSWER 109 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:626645 CAPLUS
DN 111:226645
TI Cloning and expression of human .alpha.-1-antitrypsin gene in yeast
IN Kawasaki, Glenn H.; Woodbury, Richard
PA ZymoGenetics, Inc., USA
SO U.S., 13 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------------|------|----------|-----------------|----------|
| PI US 4839283 | A | 19890613 | US 1986-946640 | 19861230 |
| PRAI US 1986-946640 | | 19861230 | | |

AB CDNA encoding .alpha.-1-antitrypsin (I) of human is cloned and expressed in yeast utilizing a wild-type strain and a hyperprodn. mutant, GK100. Yeast strains N501-B and GK100 were transformed with this plasmid. CDNA encoding human I was cloned. Plasmid HAT4 contg. the leu2 gene, triose phosphate isomerase (TPI) promoter, human I gene, and TPI terminator was constructed from plasmid C1/1. When cultured to a cell d. of .apprx.3 g/L on minimal media with 6% glucose, 2-3 % of the yeast sol. protein produced were I. In GK100 >95% of the cells had plasmid HAT4 after 30 divisions on rich media. Expression of human I using plasmid HAT4 produced .apprx.2-fold more I than those using plasmid CAT1 (without leu2 gene).

L3 ANSWER 110 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1986:221366 CAPLUS
DN 104:221366
TI Active site modified protease .alpha.1-antitrypsin inhibitors
IN Barr, Philip J.; Hallewell, Robert A.; Rosenberg, Steven; Brake, Anthony J.
PA Chiron Corp., USA
SO Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI EP 164719 | A2 | 19851218 | EP 1985-107126 | 19850610 |
| EP 164719 | A3 | 19860806 | | |
| EP 164719 | B1 | 19920506 | | |
| R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| US 4732973 | A | 19880322 | US 1984-620408 | 19840614 |
| US 4752576 | A | 19880621 | US 1984-620662 | 19840614 |
| AT 75753 | T | 19920515 | AT 1985-107126 | 19850610 |
| CA 1341165 | C | 20010116 | CA 1985-483838 | 19850613 |
| PRAI US 1984-620408 | A | 19840614 | | |
| US 1984-620662 | A | 19840614 | | |
| EP 1985-107126 | A | 19850610 | | |

AB Novel DNA constructs are described for expression of novel serine peptidase inhibitors in which the amino acid sequence analogous to human .alpha.1-antitrypsin is modified at the active site while maintaining proteinase inhibition. The methionine at the active site is substd. with an oxidatively stable amino acid, whereas other amino acids may also be changed, added, or deleted. The products have inhibitory activity to human leukocyte elastase comparable to the naturally occurring .alpha.1-antitrypsin. The proteinase inhibitors can be produced in yeast,

particularly *Saccharomyces carlsbergensis/S. cerevisiae* hybrid strain AB110 (contg. plasmid pC1/1GAPATi9).

L3 ANSWER 111 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1986:473752 CAPLUS
DN 105:73752
TI Enhanced yeast transcription employing hybrid promoter region constructs
IN Rosenberg, Steven; Tekamp-Olson, Patricia
PA Chiron Corp., USA
SO Eur. Pat. Appl., 49 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 164556 | A2 | 19851218 | EP 1985-105405 | 19850503 |
| | EP 164556 | A3 | 19870114 | | |
| | EP 164556 | B1 | 19940302 | | |
| | R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| | EP 480480 | A2 | 19920415 | EP 1991-121606 | 19850503 |
| | EP 480480 | A3 | 19920610 | | |
| | R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| | AT 102250 | T | 19940315 | AT 1985-105405 | 19850503 |
| | CA 1281671 | C | 19910319 | CA 1985-481401 | 19850513 |
| | US 5089398 | A | 19920218 | US 1989-380783 | 19890718 |
| | US 5349059 | A | 19940920 | US 1993-42134 | 19930402 |
| | US 35749 | E | 19980317 | US 1996-710744 | 19960920 |
| PRAI | US 1984-609540 | A | 19840511 | | |
| | US 1983-468589 | B2 | 19830222 | | |
| | EP 1985-105405 | A | 19850503 | | |
| | US 1987-73381 | B1 | 19870713 | | |
| | US 1989-380783 | A1 | 19890718 | | |
| | US 1990-635048 | B1 | 19901228 | | |
| | US 1993-42134 | A5 | 19930402 | | |

AB Yeast promoters of glycolytic enzyme genes are modified by isolating a fragment that encompasses the RNA polymerase binding site and joining to the 5' end of this fragment a DNA sequence that provides for enhanced inducible or constitutive transcription of a structural gene. These constructs are capable of efficient expression of foreign genes in yeast. Thus, hybrid constructions were prep'd. in which the GAL1, GAL10, or PHO5 regulatory regions were linked to the 5' end of a 200-500 bp fragment of the 5'-untranslated region of the yeast glyceraldehyde-3-phosphate dehydrogenase or pyruvate kinase gene. These latter regions contain the ribosome binding sites, extend downstream to at least nucleotide -10, and are proximal to the structural gene that they regulate. Plasmid vectors were constructed that contained the structural genes for hepatitis B surface antigen, .alpha.1-antitrypsin, and superoxide dismutase under the regulation of the above regions. These vectors exhibited improved transcription in yeast.

L3 ANSWER 112 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1986:63387 CAPLUS
DN 104:63387
TI .alpha.-1-Antitrypsin mutants, DNA coding for them and therapeutic formulations using these mutants
IN Insley, Margaret Y.; Kawasaki, Glenn Hitoshi
PA ZymoGenetics, Inc., USA
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|------|---|------|----------|-----------------|----------|--|
| PI | EP 155188 | A2 | 19850918 | EP 1985-301790 | 19850314 | |
| | EP 155188 | A3 | 19860813 | | | |
| | EP 155188 | B1 | 19931229 | | | |
| | R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | | |
| | US 4711848 | A | 19871208 | US 1985-709382 | 19850307 | |
| | AU 8539819 | A | 19850919 | AU 1985-39819 | 19850313 | |
| | AU 593766 | B2 | 19900222 | | | |
| | CA 1341219 | C | 20010501 | CA 1985-476337 | 19850313 | |
| | JP 61012289 | A | 19860120 | JP 1985-51553 | 19850314 | |
| | JP 2539781 | B2 | 19961002 | | | |
| | EP 566158 | A1 | 19931020 | EP 1993-107971 | 19850314 | |
| | R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | | |
| | AT 99358 | T | 19940115 | AT 1985-301790 | 19850314 | |
| | JP 10113193 | A | 19980506 | JP 1997-275648 | 19850314 | |
| | JP 06105689 | A | 19940419 | JP 1993-115129 | 19930406 | |
| | JP 2750257 | B2 | 19980513 | | | |
| PRAI | US 1984-589410 | A | 19840314 | | | |
| | US 1985-709382 | A | 19850307 | | | |
| | EP 1985-301790 | A | 19850314 | | | |
| | JP 1993-115129 | A3 | 19850314 | | | |
| AB | The gene for human .alpha.1-antitrypsin (I) [9041-92-3] is subjected to site-directed mutagenesis and cloning to produce a protein with enhanced stability or antithrombin [9000-94-6] activity. Substitution of methionine-358 in the active site with other amino acids protects the protein from oxidn. Substitution of lysine for glutamic acid-342 produces the Z-allele variant, which is nonimmunogenic when administered to patients homozygous for the Z-allele. [Arg358]I has antithrombin activity and maybe useful as an anticoagulant. For example, site-directed mutagenesis was carried out by annealing an oligonucleotide contg. a desired mutant codon for either position 342 or 358, together with the universal primer of phage M13, to single-stranded recombinant M13 DNA contg. the wild-type I gene. Active phage was produced by oligonucleotide extension, and ligation, and transfection into competent Escherichia coli K12. The mutant I coding region was removed by digestion with BamHI and PstI and inserted into an expression vector, e.g. M13 mp 10. | | | | | |

Day : Friday
Date: 2/23/2007

Time: 13:45:03

PALM INTRANET**Inventor Name Search Result**

Your Search was:

Last Name = FERKOL

First Name = THOMAS

| Application# | Patent# | Status | Date Filed | Title | Inventor Name |
|--------------------------|-------------------------|--------|------------|---|-----------------------|
| 09114475 | 6077835 | 150 | 07/13/1998 | NUCLEIC ACID TO CELLS DELIVERY OF COMPACTED | FERKOL JR., THOMAS W. |
| 08957333 | 6072041 | 150 | 10/24/1997 | FUSION PROTEINS FOR PROTEIN DELIVERY | FERKOL, THOMAS |
| 09559393 | 6287817 | 150 | 04/26/2000 | Fusion proteins for protein delivery | FERKOL, THOMAS |
| 60145970 | Not Issued | 159 | 07/29/1999 | ENHANCED DELIVERY VIA SERPIN ENZYME COMPLEX RECEPTOR | FERKOL, THOMAS |
| 10703206 | Not Issued | 161 | 11/07/2003 | Enhanced delivery via serpin enzyme complex receptor | FERKOL, THOMAS W. |
| 11455791 | Not Issued | 30 | 06/20/2006 | Enhanced delivery via serpin enzyme complex receptor | FERKOL, THOMAS W. |
| 08655705 | 5972900 | 150 | 06/03/1996 | DELIVERY OF NUCLEIC ACID TO CELLS | FERKOL, THOMAS W. |
| 08656906 | 5972901 | 150 | 06/03/1996 | SERPIN ENZYME COMPLEX RECEPTOR - MEDIATED GENE TRANSFER | FERKOL, THOMAS W. |
| 08716415 | 5877302 | 150 | 02/12/1997 | COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS | FERKOL, THOMAS W. |
| 08721094 | 5844107 | 150 | 09/27/1996 | COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS | FERKOL, THOMAS W. |
| 09054453 | 6008336 | 150 | 04/03/1998 | COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS | FERKOL, THOMAS W. |
| 09217847 | 6200801 | 150 | 12/21/1998 | SERPIN ENZYME COMPLEX RECEPTOR- MEDIATED GENE TRANSFER | FERKOL, THOMAS W. |
| 09264032 | 6261787 | 150 | 03/08/1999 | BIFUNCTIONAL MOLECULES FOR DELIVERY OF | FERKOL, THOMAS W. |

| | | | | | |
|----------|------------|-----|------------|---|--------------------|
| | | | | THERAPEUTICS | |
| 08216534 | Not Issued | 161 | 03/23/1994 | COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS | FERKOL,, THOMAS W. |

Inventor Search Completed: No Records to Display.

Search Another: Inventor

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

Day : Friday
 Date: 2/23/2007

Time: 13:47:15

PALM INTRANET**Inventor Name Search Result**

Your Search was:

Last Name = DAVIS

First Name = PAMELA

| Application# | Patent# | Status | Date Filed | Title | Inventor Name |
|--------------------------|------------|--------|------------|---|------------------|
| 08957333 | 6072041 | 150 | 10/24/1997 | FUSION PROTEINS FOR PROTEIN DELIVERY | DAVIS, PAMELA |
| 10290402 | 6810883 | 150 | 11/08/2002 | ELECTRICALLY HEATED CIGARETTE SMOKING SYSTEM WITH INTERNAL MANIFOLDING FOR PUFF DETECTION | DAVIS, PAMELA |
| 10837572 | Not Issued | 30 | 05/04/2004 | Electrically heated cigarette smoking system with internal manifolding for puff detection | DAVIS, PAMELA |
| 60003029 | Not Issued | 159 | 08/31/1995 | DIET TO TREAT CYSTIC FIBROSIS | DAVIS, PAMELA |
| 06711551 | Not Issued | 166 | 03/14/1985 | OSCILATING PRESSURE DEVICE FOR DYNAMIC CALIBRATION OF PRESSURE TRANSDUCERS | DAVIS, PAMELA A. |
| 06890983 | 4698997 | 150 | 07/30/1986 | OSCILLATION PRESSURE DEVICE FOR DYNAMIC CALIBRATION OF PRESSURE TRANSDUCERS | DAVIS, PAMELA A. |
| 09512260 | 6770739 | 150 | 02/24/2000 | ENHANCERS OF CFTR CHLORIDE CHANNEL FUNCTION | DAVIS, PAMELA B. |
| 09559393 | 6287817 | 150 | 04/26/2000 | Fusion proteins for protein delivery | DAVIS, PAMELA B. |
| 09914213 | Not Issued | 161 | 12/17/2001 | Enhancers of cftr chloride channel function | DAVIS, PAMELA B. |
| 10703206 | Not Issued | 161 | 11/07/2003 | Enhanced delivery via serpin enzyme complex receptor | DAVIS, PAMELA B. |
| 10743381 | Not Issued | 161 | 12/23/2003 | Enhancers of CFTR chloride channel function | DAVIS, PAMELA B. |
| 11455791 | Not Issued | 30 | 06/20/2006 | Enhanced delivery via serpin enzyme complex receptor | DAVIS, PAMELA B. |

| | | | | | |
|---------------------------------|------------|-----|------------|---|---------------------|
| <u>60687511</u> | Not Issued | 159 | 06/03/2005 | Methods and compositions for treating inflammation | DAVIS, PAMELA B. |
| <u>08655705</u> | 5972900 | 150 | 06/03/1996 | DELIVERY OF NUCLEIC ACID TO CELLS | DAVIS, PAMELA B. |
| <u>08656906</u> | 5972901 | 150 | 06/03/1996 | SERPIN ENZYME COMPLEX RECEPTOR - MEDIATED GENE TRANSFER | DAVIS, PAMELA B. |
| <u>09217847</u> | 6200801 | 150 | 12/21/1998 | SERPIN ENZYME COMPLEX RECEPTOR- MEDIATED GENE TRANSFER | DAVIS, PAMELA B. |
| <u>09264032</u> | 6261787 | 150 | 03/08/1999 | BIFUNCTIONAL MOLECULES FOR DELIVERY OF THERAPEUTICS | DAVIS, PAMELA B. |
| <u>60121495</u> | Not Issued | 159 | 02/24/1999 | ENHancers of CFTR CHLORIDE CHANNEL FUNCTION | DAVIS, PAMELA B. |
| <u>60145970</u> | Not Issued | 159 | 07/29/1999 | ENHANCED DELIVERY VIA SERPIN ENZYME COMPLEX RECEPTOR | DAVIS, PAMELA B. |
| <u>10252012</u> | Not Issued | 161 | 09/23/2002 | Q4N2NEG2 enhances CFTR activity | DAVIS, PAMELA BOWES |
| <u>60323724</u> | Not Issued | 159 | 09/21/2001 | Q4N2NEG2 enhances CFTR activity | DAVIS, PAMELA BOWES |
| <u>29127865</u> | Not Issued | 160 | 08/14/2000 | Hawaiian magnetic cake decorating spin game | DAVIS, PAMELA CAPPs |
| <u>60881095</u> | Not Issued | 20 | 01/19/2007 | Under the dryer protector | DAVIS, PAMELA LEORA |
| <u>10062778</u> | Not Issued | 161 | 02/05/2002 | Sleeve for beverage containers | DAVIS, PAMELA SUE |
| <u>09356731</u> | 6058943 | 150 | 07/18/1999 | FORMULATION AND METHOD FOR SMOOTHING AND WAVING MULTI-TEXTURED HAIR | DAVISHARRIS, PAMELA |

Inventor Search Completed: No Records to Display.

| Search Another: Inventor | Last Name | First Name |
|--------------------------|---------------------------------------|------------|
| | Davis | Pamela |
| | <input type="button" value="Search"/> | |

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

Day : Friday
 Date: 2/23/2007

Time: 13:48:11

PALM INTRANET**Inventor Name Search Result**

Your Search was:

Last Name = ZIADY

First Name = ASSEM

| Application# | Patent# | Status | Date Filed | Title | Inventor Name |
|--------------------------|------------|--------|------------|--|--------------------|
| 10477211 | Not Issued | 160 | 01/01/0001 | Enhanced delivery via serpin enzyme complex receptor | ZIADY, ASSEM |
| 10703206 | Not Issued | 161 | 11/07/2003 | Enhanced delivery via serpin enzyme complex receptor | ZIADY, ASSEM |
| 11455791 | Not Issued | 30 | 06/20/2006 | Enhanced delivery via serpin enzyme complex receptor | ZIADY, ASSEM |
| 60145970 | Not Issued | 159 | 07/29/1999 | ENHANCED DELIVERY VIA SERPIN ENZYME COMPLEX RECEPTOR | ZIADY, ASSEM |
| 09217847 | 6200801 | 150 | 12/21/1998 | SERPIN ENZYME COMPLEX RECEPTOR- MEDIATED GENE TRANSFER | ZIADY, ASSEM-GALAL |

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page